Dr Edward Joseph Brennan Jr, MD | |
682 Malin Rd, Newtown Square, PA 19073-2613 | |
(484) 680-1844 | |
Not Available |
Full Name | Dr Edward Joseph Brennan Jr |
---|---|
Gender | Male |
Speciality | Surgery |
Location | 682 Malin Rd, Newtown Square, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396237707 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | MD044608L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Edward Joseph Brennan Jr, MD 682 Malin Rd, Newtown Square, PA 19073-2613 Ph: (610) 355-0316 | Dr Edward Joseph Brennan Jr, MD 682 Malin Rd, Newtown Square, PA 19073-2613 Ph: (484) 680-1844 |
News Archive
A new study published today in the Journal of the American Medical Association (JAMA) found that the federal government made about $13 billion in duplicative payments to provide health-care services to veterans who were simultaneously enrolled in Medicare Advantage plans from 2004-2009.
Regenerative medicine using stem cells is an increasingly promising approach to treat many types of injury. Transplanted stem cells can differentiate into just about any other kind of cell, including neurons to potentially reconnect a severed spinal cord and repair paralysis.
The Canadian Red Cross has committed $1 million to support relief efforts in Kenya and Somalia. This money will be used to support the Kenya Red Cross Society and the Somali Red Crescent in their efforts to help provide immediate life-saving assistance and help people recover their livelihoods.
A method for "silencing" RNA that emerged from a University of Wisconsin-Madison spinoff company is in clinical trials in Europe, Asia and the United States against hepatitis B, an infection that can destroy the liver.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
› Verified 3 days ago
Loren Berman, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3855 W Chester Pike, Suite 280, Newtown Square, PA 19073 Phone: 610-557-4800 Fax: 610-557-4816 | |
Dr. Mahin D Behbehanian, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3723 Rosemont Pass, Newtown Square, PA 19073 Phone: 610-745-6701 Fax: 610-565-7426 | |
Dr. Christian R Subbio, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 3734 West Chester Pike, Newtown Square, PA 19073 Phone: 610-356-6100 Fax: 610-356-6108 |